Payday? Here's why the CSL share price is sliding this morning…

The CSL share price is underperforming today, but for good reason…

| More on:
a woman looks down at her phone with a look of concern on her face and her hand held to her chin while she seriously digests the news she is receiving.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The ASX 200 has had a rough start to the week so far on Monday
  • But CSL shares are faring even worse
  • CSL shares are trading ex-dividend today

The S&P/ASX 200 Index (ASX: XJO) has had a bit of a topsy-turvy start to the trading week so far this Monday. At the time of writing, the ASX 200 is down by 0.64% after spending time in both positive and negative territory already today. But let's check out what the CSL Limited (ASX: CSL) share price is up to.

At the time of writing, CSL shares are trading for $254.12 each. That's down around 1.62% so far.

So is there any good reason why CSL shares might be trailing the broader market so decisively today?

Well, as it happens, there is.

Today is a big day on the CSL shareholder calendar. It is the day this ASX 200 healthcare company trades ex-dividend for its upcoming interim payment. Last month, CSL delivered its half-year earnings report. Along wth a mixed-bag of results, this naturally included details about CSL's next dividend payment.

This upcoming dividend will be worth US$1.04 per share for investors when it is paid out on 6 April. The final value in Australian dollars is yet to be determined. But it works out to be approximately $1.41 on today's exchange rates. The dividend will come unfranked. At US$1.04 per share, it is also flat on last year's interim dividend.

So the fact that this dividend has now gone 'ex' is probably at least partially why the CSL share price is showing weakness today. When a company trades ex-dividend, the value of the dividend payment in question leaves the company's share price. That's because, from today, no new CSL shareholders will be entitled to receive the company's upcoming payment. This means the shares are effectively worth less today than they were on Friday.

CSL share price snapshot

Like many ASX 200 shares, CSL hasn't had the easiest ride in 2022 so far. This healthcare giant has lost more than 14% year to date. However, the company is still up around 3.5% over the past 12 months, and up more than 102% over the past five years.

At the current CSL share price, the company has a market capitalisation of $124.7 billion, with a dividend yield of 1.14%.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

A leading expert forecasts more growth ahead for this $32 billion ASX 200 healthcare company.

Read more »

A scientist examining test results.
Healthcare Shares

1 ASX dividend stock down 43% I'd buy right now

This business could provide both dividends and growing, defensive earnings.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Why FDA approval could turn this ASX All Ords company into a multibagger

Despite surging more than 230% in the past year, this company might be on its way to becoming a much…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares

Canaccord Genuity recommends a 'basket approach' when investing in these types of stocks.

Read more »

A worried woman looks at her phone and laptop, seeking ways to tighten her belt against inflation.
Healthcare Shares

This ASX share potentially 'has no value from here', says broker

This is every investor's worst nightmare.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Healthcare Shares

Should I buy Fisher & Paykel or ResMed shares?

Let's see which of these two names could be best buys.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This company has entered a trading halt, is it about to announce FDA approval?

This regenerative medicine company is up more than 260% in the last year.

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

How are Cochlear shares impacted by Trump's tariffs?

Will the company escape from the tariffs? Let's find out.

Read more »